about
Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.Fondaparinux - data on efficacy and safety in special situations.A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenonDiagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis.Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia.Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia.Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice.Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort studyRetrospective adjustment of self-assessed medical competencies - noteworthy in the evaluation of postgraduate practical training courses.Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation studyEpistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon.Severe hyperkalemia and bilateral adrenal metastasis.Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study.Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic syndrome).Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice.Impact of changes in haematocrit level and platelet count on thromboelastometry parameters.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.Impact of rivaroxaban on point-of-care assays.Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia.Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcomeShort-term recovery pattern of plasma fibrinogen after cardiac surgery: A prospective observational studyNext generation viscoelasticity assays in cardiothoracic surgery: Feasibility of the TEG6s systemThromboembolien und Thrombophilie in der SchwangerschaftThrombophilieabklärungDiagnostic value of the 4Ts score for heparin-induced thrombocytopenia in the critically illRisk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction.Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valveLeeching as a substitute for phlebotomyIron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemiaAdherence to treatment with non-vitamin K antagonist anticoagulants: once- vs. twice-daily regimens[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests]Accuracy of the point-of-care coagulometer CoaguChek XS in the hands of patientsPatient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: comment on Jennings, et al British Journal of Haematology, 2014, 167:600-607[New oral anticoagulants - influence on coagulation tests]Consistency of thromboelastometry analysis under scrutiny: results of a systematic evaluation within and between analysersThromboelastometry changes in myeloproliferative neoplasms-surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons? : Comment on A. Tripodi et al. Ann Hematol (2013) 92:1633-1639Predictors of anticoagulation quality in 15 834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated
P50
Q31112836-82C5B31B-1005-4C52-8745-D34A4E8BFBCFQ33398519-2D700907-936E-424B-98FB-63EA4DFDC26FQ33415150-8B576B48-3914-411F-972C-471CB5E85D45Q33427187-5A239C8D-4753-4534-BCDE-35FBCC2D6C89Q33435213-450B5EE6-04EF-4C7D-B902-E169B4570FBAQ33439939-61B75B08-19AE-4683-A0EF-7A09540548BAQ33442535-385EEBA2-EBB7-4AB7-B20F-5F13748CD440Q33659495-064B8DC5-C6FB-4457-ACA7-80C369800CFCQ35153009-4F1DDA46-FD3C-4E4C-B968-C99B8C66CECAQ36028710-11AC470C-E2F8-4744-BFFE-FA1D2D7C3406Q36689644-6756F453-3AA2-49E4-8B3D-3C09B812DD7EQ38782928-1002E3C6-7014-403F-B37B-CF1F50EA429BQ39369930-8A791E53-8BB4-486A-8B1E-E9F789DBF844Q40185654-825A631A-2363-427F-8A35-D9C4CF430441Q41342074-6C6A0D72-9C47-4D92-8466-EA91F718BEEDQ41812474-A994CC1E-DE51-4280-8FD6-B52C0D45E9ADQ46551187-5521B847-672F-46AE-A88A-F47A39A09C2EQ47728750-E1C1CD69-C662-42D6-9362-8D049975D731Q48336080-DD101890-2373-40B0-95E6-D36D2B9E9771Q50773461-832EE773-F952-4BC5-84A2-D52F66218301Q53090944-1961A3F9-6193-450D-8B75-FD694E8F9388Q55337905-0DD64CDB-314D-41BD-B335-0BCEC7823046Q58696080-84011471-607F-45B6-9455-72671F21BF07Q58802490-A72A9E7B-E4DE-42F7-8126-7F39B9906934Q60945019-D207928D-73F0-4819-AE1B-69F6E9BA680DQ62383678-2ADB8EE2-1B8B-4857-AAAE-966C2A1EC2A3Q62383680-4EED77B0-16E2-44A2-8A36-32B569452F2DQ62383691-FF079277-E3F3-43A3-BA8E-C299CE3B52A0Q64905654-9DE14CA0-B267-40EB-A230-F7BA0848E480Q83130986-C0795D0B-831F-4289-9FA0-571ACBDED735Q83630024-1AD60185-CE3B-49E9-A13B-07C21FB60749Q84323425-49C99A53-D77B-4413-AFE3-A6D224D1E238Q85315580-6A8F41CA-5A61-45F5-981E-FF6CB6D85DAAQ85334873-8A5A6B25-211E-4F59-B430-763EC29C8BBAQ85346926-7DBADA89-9D38-4F8E-BC25-99DBBCD74BCCQ86016611-49D99D15-BCF1-4162-9115-8DD2C74E4EF1Q87051207-41C04682-9779-4C9B-9830-2808D4F31121Q87192915-61A11B87-2701-4F8D-A617-745879217FD4Q87672903-BED03DB7-8A15-491C-9390-43C876B3FDB8Q88015283-8B37A4AC-DAC1-47C5-A959-6D3E29C49339
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Nagler
@ast
Michael Nagler
@en
Michael Nagler
@es
Michael Nagler
@fr
Michael Nagler
@nl
type
label
Michael Nagler
@ast
Michael Nagler
@en
Michael Nagler
@es
Michael Nagler
@fr
Michael Nagler
@nl
altLabel
M. Nagler
@en
M. Nagler
@es
M. Nagler
@fr
prefLabel
Michael Nagler
@ast
Michael Nagler
@en
Michael Nagler
@es
Michael Nagler
@fr
Michael Nagler
@nl
P106
P1153
36706325500
P31
P496
0000-0003-4319-2367